dual-target therapy
Dual-Target Anti-VEGF Race Heats Up with RemeGen-Santen $180M Deal
RemeGen’s $180M deal with Santen for RC28-E, a VEGF/FGF dual-target drug, highlights the growing anti-VEGF race in China’s eye drug market, where dual-target therapies and biosimilars, including Vabysmo and Conbercept, are reshaping wAMD and DME treatment.